(E)-1-cyclopropyl-3-quinolin-3-yl-propenone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (E)-1-cyclopropyl-3-quinolin-3-yl-propenone
• 英文别名: 1-cyclopropyl-3-quinolin-3-yl-propenone；(E)-1-cyclopropyl-3-quinolin-3-ylprop-2-en-1-one
• 化学式: C₁₅H₁₃NO
• 分子量: 223.274
• InChiKey: BNUARCYGDSEHNY-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-喹啉甲醛 、 环丙甲基酮 生成 (E)-1-cyclopropyl-3-quinolin-3-yl-propenone
  参考文献：
  名称：

  Cyclic and acyclic propenones for treating CNS disorders

  摘要：

  该发明涉及新颖的环状和非环状丙烯酮衍生物以及它们的药用可接受盐。该发明还涉及一种制备这类化合物的方法。该发明的化合物可用作药物。

  公开号：

  US20060074083A1

文献信息

• Cyclic and acyclic propenones for treating CNS disorders
  申请人：Kalvinsh Ivars

  公开号：US20060074083A1

  公开（公告）日：2006-04-06

  The invention relates to novel cyclic and non-cyclic propenone derivatives as well as their pharmaceutically acceptable slats. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are useful as medicaments.

  该发明涉及新颖的环状和非环状丙烯酮衍生物以及它们的药用可接受盐。该发明还涉及一种制备这类化合物的方法。该发明的化合物可用作药物。
• [EN] NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS<br/>[FR] NOUVELLES PROPENONES CYCLIQUES ET ACYCLIQUES DESTINEES AU TRAITEMENT DES TROUBLES DU SNC
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2006037996A1

  公开（公告）日：2006-04-13

  The invention relates to novel cyclic and non-cyclic propenone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are useful as medicaments.
• Synergism of virtual screening and medicinal chemistry: Identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1
  作者：Tobias Noeske、Dina Trifanova、Valerjans Kauss、Steffen Renner、Christopher G. Parsons、Gisbert Schneider、Tanja Weil

  DOI：10.1016/j.bmc.2009.05.072

  日期：2009.8

  We report the identification of novel potent and selective metabotropic glutamate receptor 1 (mGluR1) antagonists by virtual screening and subsequent hit optimization. For ligand-based virtual screening, molecules were represented by a topological pharmacophore descriptor (CATS-2D) and clustered by a self-organizing map (SOM). The most promising compounds were tested in mGluR1 functional and binding assays. We identified a potent chemotype exhibiting selective antagonistic activity at mGluR1 ( functional IC50 = 0.74 +/- 0.29 mu M). Hit optimization yielded lead structure 16 with an affinity of K-i = 0.024 +/- 0.001 mu M and greater than 1000-fold selectivity for mGluR1 versus mGluR5. Homology-based receptor modelling suggests a binding site compatible with previously reported mutation studies. Our study demonstrates the usefulness of ligand-based virtual screening for scaffold-hopping and rapid lead structure identification in early drug discovery projects. (C) 2009 Elsevier Ltd. All rights reserved.